Dopamine Receptor Subtypes as Targets for the Pharmacotherapy of Parkinson's Disease

Advances in Pharmacology

Volumn 42, Issue C, 1997, Pages 792-795

  Andringa, G ^a,b   Vermeulen, R J ^a   Drukarch, B ^a   Stoof, J C ^a   Cools, A R ^b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0013489793     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60866-2     Document Type: Article

References (4)

1. Vermeulen R.J., Drukarch B., Sahadat M.C.R., Goosen G., Wolters E.G., and Stoof J.C. The selective D1 receptor agonist SKF 81297 stimulates motor behavior of MPTP-lesioned monkeys. Eur. J. Pharmacol. 235 (1993) 143
2. Blanchet P.J., Grondin R., and Bedard P.J. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri- dine-lesioned primates. Mov. Disord. 11 (1996) 91
3. Starr M.S., and Starr B.S. Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. J. Neural Transm. Park. Disease Dem. Sect. 6 (1993) 27
4. Gnanalingham K.K., Erol D.D., Hunter A.J., Smith L.A., Jenner P., and Marsden C.D. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology 117 (1995) 275